Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

[1]  C. Cannon,et al.  Should real-world evidence be incorporated into regulatory approvals? , 2018, Expert opinion on drug safety.

[2]  A. Konstas,et al.  Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients , 2018, Expert opinion on pharmacotherapy.

[3]  Karl Broich,et al.  Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? , 2018, Clinical pharmacology and therapeutics.

[4]  Kofi Fred Asiedu,et al.  The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review , 2018, Journal of current ophthalmology.

[5]  C. Birt,et al.  Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) , 2016, Expert opinion on drug metabolism & toxicology.

[6]  K. Kaarniranta,et al.  Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies , 2016, Clinical Pharmacokinetics.

[7]  Sheridan M. Hoy.  Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension , 2015, Drugs.

[8]  G. Holló,et al.  Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma , 2015, Expert opinion on drug safety.

[9]  F. Topouzis,et al.  Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice , 2014, Expert opinion on pharmacotherapy.

[10]  G. Holló,et al.  Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[11]  I. Floriani,et al.  Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  J. García-Feijóo,et al.  A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma , 2012, Clinical ophthalmology.

[13]  L. Rossetti,et al.  Prostaglandin-Timolol Fixed Combinations Efficacy: Myth or Reality? , 2012, European journal of ophthalmology.

[14]  M. Cucherat,et al.  Efficacy and Tolerability of Prostaglandin-Timolol Fixed Combinations: A Meta-Analysis of Randomized Clinical Trials , 2011, European journal of ophthalmology.

[15]  C. Birt,et al.  Preservative Exposure and Surgical Outcomes in Glaucoma Patients: The PESO Study , 2011, Journal of glaucoma.

[16]  Susana Molina-Castañer,et al.  Terminology and guidelines for glaucoma , 2009 .

[17]  C. Baudouin.  Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma , 2008, Acta ophthalmologica.

[18]  A. Konstas,et al.  A review of additivity to prostaglandin analogs: fixed and unfixed combinations. , 2008, Survey of ophthalmology.

[19]  Robert N Weinreb,et al.  Prevalence of Ocular Surface Disease in Glaucoma Patients , 2008, Journal of glaucoma.

[20]  C. Erb,et al.  German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  T. Zeyen,et al.  Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications , 2007, European journal of ophthalmology.

[22]  A. Bron,et al.  Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests , 2003, Cornea.

[23]  M. C. Leske,et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.

[24]  C. Baudouin,et al.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication , 2002, The British journal of ophthalmology.

[25]  R. P. Mills,et al.  The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. , 2001, Ophthalmology.

[26]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[27]  Douglas R. Anderson,et al.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. , 1998, American journal of ophthalmology.

[28]  V. P. Bhapkar.  A Note on the Equivalence of Two Test Criteria for Hypotheses in Categorical Data , 1966 .

[29]  M. Irkec,et al.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages , 2017, Drugs.

[30]  N. Pfeiffer,et al.  A 6-Month Study Comparing Efficacy , Safety , and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0 . 0015 % and Timolol 0 . 5 % versus Each of Its Individual Preservative-Free Components , 2014 .

[31]  N. Pfeiffer,et al.  Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. , 2014, Advances in therapy.

[32]  Hannu UusitaloYury.  A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free , 2014 .

[33]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .